Author

Naomi Sinclair

Newcastle University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrew Michael FreyiD· 1 shared Andrew PauliD· 1 shared Christopher J. LordiD· 1 shared Christopher P. A. T. LawsoniD· 1 shared David R. AdamsiD· 1 shared Emily StephensoniD· 1 shared Éva ÁdámiD· 1 shared Gary ReynoldsiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew Michael FreyORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.

Kirsty Hodgson, Joseph Inns, Gary Reynolds, Emily Stephenson, Andrew Paul, Naomi Sinclair, Giacomo Berretta, Christopher P. A. T. Lawson, Andrew Michael Frey, Iglika G. Ivanova, Éva Ádám, Christopher J. Lord, Simon Cockell, Jonathan M Coxhead, Nikoletta Nagy, , Neil Rajan

This study identifies non-canonical NF-κB signalling as a therapeutic target in CYLD cutaneous syndrome and shows that IKK inhibition reduces tumor viability in patient-derived models.

bioRxiv · Jan 31, 2025 · PreprintCancer Biology